An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

September 29, 2025

Primary Completion Date

May 3, 2029

Study Completion Date

May 17, 2029

Conditions

Multiple System Atrophy

Interventions

DRUG

TEV-56286

administered orally

All Listed Sponsors

lead

Teva Branded Pharmaceutical Products R&D LLC

INDUSTRY

NCT07197866 - An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy | Biotech Hunter | Biotech Hunter